Abstract 2365: Overall Experience with the Tandem Heart™ at the Texas Heart Institute
OBJECTIVE: The Tandem Heart™ is a low-speed continuous-flow percutaneously placed left ventricular assist device capable of up to 4.5L/min of assisted cardiac output and therefore very useful in a number of high-risk clinical settings. We sought to document our overall experience with the Tandem Heart™at the Texas Heart Institute.
RESULTS: Tandem Heart™ devices where placed in 42 patients from May 2003 to April 2006. The average age was 59.3 ± 16.4 years; 28 were males and 14 were females. The NICM patients included 3 with severe myocarditis, one with peripartum cardiomyopathy, one with end-stage sarcoid cardiomyopathy, and 10 with idiopathic dilated cardiomyopathy. Tandem Heart™ support was used in 6 extremely high-risk patients undergoing PCI (none were surgical candidates) in whom IABP was judged to be insufficient and percutaneous cardiopulmonary bypass was not an option. Overall survival at 30 days and 6 months for all 42 patients was 61% and 50%, respectively.
CONCLUSIONS: In addition to being an effective means of left ventricular hemodynamic support in patients with severe, refractory cardiogenic shock, the Tandem Heart™ can also be considered in unstable patients as a means of support for bridge to LVAD or orthotopic hear transplant, and cardiovascular support in high-risk PCI, CABG and surgical valve repair.